Abivax

Anti-viralsVaccinesFrance

Paris-based Abivax, in collaboration with the Cuban Center for Genetic Engineering and Biotechnology, is the creation of French venture capital firm Truffle Capital.

Paris-based Abivax, in collaboration with the Cuban Center for Genetic Engineering and Biotechnology, is the creation of French venture capital firm Truffle Capital.

Abivax is the first ever start-up launched on the basis of a Euro-Cuban R&D collaboration. Abivax aims to become a global leader in therapeutic vaccines and antivirals, leveraging both its existing product pipelines and future acquisitions that are currently in negotiations.

Abivax specializes in therapeutic vaccines and antivirals, combining the technologies and the product portfolios of three French biotech companies financed by Truffle Capital (Wittycell, Splicos and Zophis). An exclusive partnership agreement with the CIGB has been approved by the Cuban government and will further enrich the portfolio.

Abivax already possesses several key assets by itself including a set of complementary technology platforms, a high-value product portfolio and an experienced top management team.


Latest Articles

Back to top